Cancers have an altered lipid-metabolic-reprogramming [187], over-express Low Density Lipoprotein Receptors (LDLR) [188] and take in more LDLs and albumin than normal cells, to the extent that a cancer patient’s LDL- and albumin-counts can even go down [189]; LDL-uptake promotes aggressive phenotypes [190] resulting in proliferation and invasion in breast cancer [191], and an abundance of LDL-Receptors is a prognostic indicator of metastatic potential [192]. The gene discussed is LDLR; the disease is cancer.